Evolus, Inc. (EOLS) Stock
Key stats
- Market cap
- $491.12M
- Price / Earnings ratio
- -14.5x
- EPS (TTM)
- -$0.47
- Volume
- Loading
- 52-week high
- $9.31
- 52-week low
- $3.86
Source: third-party data provider, as of November 13, 2026
Compare with EOLS
Recent news
Evolus to Participate in Upcoming Investor Conferences in New York and London
Evolus to Participate in Upcoming Investor Conferences in New York and London
EOLS
Evolus to Report Third Quarter Financial Results on November 4, 2026
Evolus to Report Third Quarter Financial Results on November 4, 2026
EOLS
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
EOLS
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
EOLSNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.33
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.16
- MACD histogram
- 0.00
- SMA 50
- $7.70
- Price below SMA 50
- EMA 50
- $7.45
- Price below EMA 50
- SMA 200
- $6.35
- Price above SMA 200
- EMA 200
- $6.67
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.05 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Evolus to Participate in Upcoming Investor Conferences in New York and London
Evolus to Participate in Upcoming Investor Conferences in New York and London
EOLSEvolus to Report Third Quarter Financial Results on November 4, 2026
Evolus to Report Third Quarter Financial Results on November 4, 2026
EOLSEvolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
EOLSEOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
EOLS
FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action
FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action
EOLS
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
EOLS
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
EOLS
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
EOLS
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
EOLS
Evolus Q2 Earnings Call Highlights
Evolus Q2 Earnings Call Highlights
EOLSNews tone: automated (AI) classification of the article's content, not a price prediction.
About Evolus, Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. David Moatazedi | President, CEO & Director | 1978 |
| Ms. Tatjana Mitchell | Chief Financial Officer | — |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development | 1962 |
| Mr. Nareg Sagherian | Head of Global Investor Relations & Corporate Communications | — |
| Mr. Kurt Knab | Senior Vice President of Sales | — |
| Ms. Jessica Novak | Senior Vice President of Human Resources | — |
| Mr. Jeffrey J. Plumer | Corporate Secretary | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.33
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.16
- MACD histogram
- 0.00
- SMA 50
- $7.70
- Price below SMA 50
- EMA 50
- $7.45
- Price below EMA 50
- SMA 200
- $6.35
- Price above SMA 200
- EMA 200
- $6.67
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $13.00
- Average
- $14.00
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -22.0 | +18.6 | ||||||||||
| 2022 | +5.7 | +22.0 | +24.7 | -4.4 | +13.1 | -11.8 | +5.5 | -26.7 | -11.9 | +1.4 | -14.8 | +2.3 |
| 2023 | +32.7 | -14.6 | -6.5 | +3.3 | +4.0 | -16.1 | +38.4 | -2.8 | -7.8 | -12.3 | +23.8 | +8.0 |
| 2024 | +27.0 | +13.7 | -6.1 | -14.5 | +2.5 | -16.6 | +12.1 | +13.2 | +4.0 | -4.1 | -18.3 | -18.3 |
| 2025 | +25.7 | +12.4 | -16.1 | -4.9 | -22.1 | -7.6 | -3.0 | -16.6 | -18.1 | +5.0 | +12.1 | -2.5 |
| 2026 | -30.2 | -12.4 | -4.2 | +25.1 | +23.1 | +6.4 | -13.4 | +50.2 | -11.9 | -4.4 | +3.6 |
